Skip to main content
SpringerLink
Log in

Comparative Safety and Tolerability of Angiotensin II Receptor Antagonists

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Hypertension is a very common disease and represents a major risk factor for cardiovascular adverse events such as stroke and heart failure. In recent years, a big effort has been put into detecting and treating patients with hypertension. Several classes of drugs acting by different pharmacological mechanisms can be chosen for the treatment of hypertension. However, the long term use of all antihypertensive agents is sometimes limited by the occurrence of adverse effects. Thanks to continuous pharmacological research, new compounds are regularly developed and become available in clinical practice.

Recently, several new, nonpeptide, orally active angiotensin II receptor antagonists have reached the market. Today, these substances represent the most specific way to block the renin angiotensin system. Numerous studies have now demonstrated that these angiotensin II antagonists are as effective as ACE inhibitors, calcium antagonists, β-blockers or diuretics in lowering blood pressure in patients with hypertension.

Given the increasing use of angiotensin II receptor antagonists in the treatment of hypertension, it is important to review their safety and tolerability. Based on the actual level of knowledge, the striking feature of this class of agents is their favourable safety and tolerability profile which appears to be equivalent to that observed with placebo. Indeed, so far, no clear class-specific adverse effect has been attributed to the angiotensin II receptor antagonists. Thus, if angiotensin II antagonists prevent target organ damage and reduce the morbidity and mortality of patients with hypertension, they may well become a first-line treatment of hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74

    Article  PubMed  CAS  Google Scholar 

  2. Joint National Committee on detection of hypertension. The 5th report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC V). Arch Int Med 1993; 153: 154–83

    Article  Google Scholar 

  3. Timmermans PBMWM, Benfield P, Chiu AT, et al. Angiotensin II receptor and functional correlates. Am J Hypertens 1992; 5: 221S–35S

    PubMed  CAS  Google Scholar 

  4. Wexler RR, Carini DJ, Duncia JV, et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens 1992; 5: 209s–20s

    PubMed  CAS  Google Scholar 

  5. Burnier M, Brunner HR. Angiotensin II receptor antagonistsantihypertensive agents. Exp Opin Invest Drugs 1997; 6: 489–500

    Article  CAS  Google Scholar 

  6. Wexler RR, Greenlee WJ, Irvin JD. Non-peptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996; 39: 625–56

    Article  PubMed  CAS  Google Scholar 

  7. Mallion JM, Goldberg AI. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist in the treatment of hypertension. Blood Press 1996; 5 Suppl. 2: 82–6

    Google Scholar 

  8. McClellan JK, Goa KL. Candersartan cilexetil: a review of its use in essential hypertensions. Drugs 1998; 56(5): 847–69

    Article  PubMed  CAS  Google Scholar 

  9. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54(2): 299–311

    Article  PubMed  CAS  Google Scholar 

  10. Gillis JC, Merkham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54(6): 885–902

    Article  PubMed  CAS  Google Scholar 

  11. Mclntyre M, Coffe SE, Michalok RA, et al. Losartan, an orally active angiotensin (ATI) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74(2): 181–94

    Article  Google Scholar 

  12. Waeber M. Clinical safety and tolerability of losartan. Clin Ther 1997; 19(4): 604–16

    Article  Google Scholar 

  13. Haddad AM, Scholer SG. Possible losartan-induced rash. Am J Health Syst Pharm 1997; 54(11): 1333–4

    PubMed  CAS  Google Scholar 

  14. Bosch X. Henoch-Schönlein purpura induced by losartan therapy. Arch Int Med 1998; 158: 191–2

    Article  CAS  Google Scholar 

  15. Viraben R, Lamant L, Brousset P. Losartan-associated atypical cutaneous lymphoid hyperplasia. Lancet 1997; 350: 1366

    Article  PubMed  CAS  Google Scholar 

  16. Magro C, Crowson A. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates. Hum Pathol 1996; 27: 125–32

    Article  PubMed  CAS  Google Scholar 

  17. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234–42

    PubMed  CAS  Google Scholar 

  18. Lacourcière Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitory versus angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994; 12: 549–53

    Google Scholar 

  19. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997; 11: 483–9

    Article  PubMed  CAS  Google Scholar 

  20. Belcher G, Hübner R, George M, et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1998; 11: S85–S9

    Google Scholar 

  21. Lacourcière Y, Brunner HR, Irwing R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387–93

    PubMed  Google Scholar 

  22. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101–7

    PubMed  CAS  Google Scholar 

  23. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693–7

    Article  PubMed  CAS  Google Scholar 

  24. Vleeming W, van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 1998; 18(3): 171–88

    Article  PubMed  CAS  Google Scholar 

  25. Merck & Co., Inc. Losartan potassium prescribing information, West Point, PSA 19486, USA, 1995

  26. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan [letter]. N Engl J Med 1995; 333: 1572

    Article  PubMed  CAS  Google Scholar 

  27. van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158(18): 2063–5

    Article  PubMed  Google Scholar 

  28. Griffin J. Drug-induced disorders of taste. Adverse Drug React Toxicol 1992; 11: 229–39

    CAS  Google Scholar 

  29. Schlienger R, Saxer M, Haefli W Reversible ageusia associated with losartan. Lancet 1996; 347: 471–2

    Article  PubMed  CAS  Google Scholar 

  30. Heeringa M, van Puijenbroek EP. Reversible dysgeusia attributed to losartan. Ann Int Med 1998; 129(1): 72

    PubMed  CAS  Google Scholar 

  31. Ahmad S. Losartan and severe migraine. JAMA 1995; 274(16): 1266–7

    Article  PubMed  CAS  Google Scholar 

  32. Ahmad S. Losartan and reversible psychosis. Cardiology 1996; 87: 569–70

    Article  PubMed  CAS  Google Scholar 

  33. Shand B, Gilchrist N, Nicholls M, et al. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995; 9: 233–5

    PubMed  CAS  Google Scholar 

  34. Schwarzbeck A, Wittenmeier U. Hällfritzsch anaemia in dialysis patients as a side-effect of sartanes [letter]. Lancet 1998; 325: 286

    Article  Google Scholar 

  35. Julian BA, Brantley Jr RR, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9(6): 1104–8

    PubMed  CAS  Google Scholar 

  36. Schwarzbeck A, Wittenmeier KW, Hallfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes. Lancet 1998; 352(9124): 286

    Article  PubMed  CAS  Google Scholar 

  37. Navarro JF, Garcia J, Macia M, et al. Effects of losartan on the treatment of posttransplant erythrocytosis. Clin Nephrol 1998; 49(6): 370–2

    PubMed  CAS  Google Scholar 

  38. Ducloux D, Fournier V, Bresson-Vautrin C, et al. Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transpl Int 1998; 11(4): 312–5

    Article  PubMed  CAS  Google Scholar 

  39. Hortal L, Fernandez A, Vega N, et al. Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis. Transplant Proc 1998; 30(5): 2127–8

    Article  PubMed  CAS  Google Scholar 

  40. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am JCardiol 1995; 75: 793–5

    Article  CAS  Google Scholar 

  41. Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333–5

    Article  PubMed  CAS  Google Scholar 

  42. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339–47

    Article  PubMed  CAS  Google Scholar 

  43. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996; 49: 1787–90

    Article  PubMed  CAS  Google Scholar 

  44. Sweet CS, Bradstreet DC, Berman RS, et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035–40

    PubMed  CAS  Google Scholar 

  45. Soffer BA, Wright JT, Pratt H, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112–7

    Article  PubMed  CAS  Google Scholar 

  46. Shahinfar S, Simpson C, Carides A, et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia [abstract]. J Am Soc Nephrol 1997; 8: 322a

    Google Scholar 

  47. Minghelli G, Seydoux C, Goy J, et al. Uricosuric effect of losartan in cyclosporine-treated heart transplant recipients. Transplantation 1998; 66(2): 268–71

    Article  PubMed  CAS  Google Scholar 

  48. Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25: 602–9

    Article  PubMed  CAS  Google Scholar 

  49. Ilson BE, Martin DE, Boike SC, et al. The effects of eprosartan, an angiotensin II ATI receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998; 38(5): 437–41

    PubMed  CAS  Google Scholar 

  50. Bauer J, Reams GP. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch Int Med 1995; 155: 1361–8

    Article  CAS  Google Scholar 

  51. De Zeeuw D, Gansevoort RT, Dullaart RP, et al. Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens 1995; 13: S53–S8

    Article  Google Scholar 

  52. Moan A, Hoieggen A, Seljeflot I, et al. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14(9): 1093–7

    Article  PubMed  CAS  Google Scholar 

  53. Laakso M, Karjalainen L, Lempiäinen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392–6

    Article  PubMed  CAS  Google Scholar 

  54. Lankisch PG, Droge M, Gottesleben F. Drug-induced pancreatitis: incidence and severity. Gut 1995; 37: 565–7

    Article  PubMed  CAS  Google Scholar 

  55. Bosch X. Losartan-induced acute pancreatitis. Ann Intern Med 1997; 127: 1043–4

    PubMed  CAS  Google Scholar 

  56. Birck R, Keim V, Fiedler F, et al. Pancreatitis after losartan. Lancet 1998; 351(9110): 1178

    Article  PubMed  CAS  Google Scholar 

  57. Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 1997; 11: S91–S5

    PubMed  CAS  Google Scholar 

  58. McInnes GT, O’Kane KPJ, Jonker J, et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl. 2): S75–S80

    PubMed  CAS  Google Scholar 

  59. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333–42

    Article  PubMed  CAS  Google Scholar 

  60. Mallion JM, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with Captopril in patients with mild to moderate essential hypertension. J Hypertens 1995; 13 (Suppl. 1): 35–41

    Article  Google Scholar 

  61. Dahlöf B, Keller S, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578–83

    Article  PubMed  Google Scholar 

  62. Burrell LM, Johnston CI. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drug Ther 1997; 10: 421–34

    CAS  Google Scholar 

  63. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54(6): 885–902

    Article  PubMed  CAS  Google Scholar 

  64. Chioléro A, Burnier M. Pharmacology of valsartan, an angiotensin II receptor antagonist. Exp Opin Invest Drugs 1998; 7(11): 1915–25

    Article  Google Scholar 

  65. Sica DA, Lo MW, Shaw WC, et al. The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995; 13: S49–S52

    CAS  Google Scholar 

  66. Sica DA, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharm Ther 1997; 62(6): 610–8

    Article  CAS  Google Scholar 

  67. DeZeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997; 11 (Suppl. 2), S37–42

    CAS  Google Scholar 

  68. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403–7

    Article  PubMed  CAS  Google Scholar 

  69. Toto R, Shultz P, Raij L, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998; 31: 684–91

    Article  PubMed  CAS  Google Scholar 

  70. Gansevoort RT, De Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861–7

    Article  PubMed  CAS  Google Scholar 

  71. Pechère-Bertschi A, Nussberger J, Decosterd L, et al. Renal response to the AT1 antagonist irbesartan vs enalapril in hypertensive patients. J Hypertens 1998; 16: 385–93

    Article  PubMed  Google Scholar 

  72. Mimran A, Ribstein J, DuCailar G. Comparison of the acute renal effect of losartan and Captopril in atheromatous renovascular disease. Am J Hypertens 1998; 11: 47A

    Article  Google Scholar 

  73. Saine D, Ahrens E. Renal impairment associated with losartan. Ann Intern Med 1996; 124: 775

    PubMed  CAS  Google Scholar 

  74. Marino MR, Langenbacher KM, Raymond RH, et al. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998; 38(4): 347–56

    PubMed  CAS  Google Scholar 

  75. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharm Ther 1997; 62(3): 272–8

    Article  CAS  Google Scholar 

  76. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 8: 1602–9

    Article  Google Scholar 

  77. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J Am Coll Cardiol 1995; 26: 438–45

    Article  PubMed  CAS  Google Scholar 

  78. Crozier I, Ikram H, Awan N, et al. Circulation 1995; 91: 691–7

    Article  PubMed  CAS  Google Scholar 

  79. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus Captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349: 747–52

    Article  PubMed  CAS  Google Scholar 

  80. Kreft-Joris C, Plouin PF, Tchobroutsky C. Angiotensin converting enzyme inhibitors during pregnancy. J Hypertens 1987; 5 (Suppl. 5): 553–4

    Google Scholar 

  81. Kong AN, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995; 35: 1008–15

    PubMed  CAS  Google Scholar 

  82. Fricker A, Nussberger J, Meilenbrock S, et al. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int 1998; 54: 2089–97

    Article  PubMed  CAS  Google Scholar 

  83. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45(2): 205–51

    PubMed  CAS  Google Scholar 

  84. Stoll M, Steckenlings M, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Switzerland

    Lucia Mazzolai &  Michel Burnier

Authors
  1. Lucia Mazzolai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Burnier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Burnier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazzolai, L., Burnier, M. Comparative Safety and Tolerability of Angiotensin II Receptor Antagonists. Drug-Safety 21, 23–33 (1999). https://doi.org/10.2165/00002018-199921010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199921010-00003

Keywords

Search

Navigation